Lipid Lowering Therapy and Circulating PCSK9 Concentration

Journal of Atherosclerosis and Thrombosis - Japan
doi 10.5551/jat.rv17012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japan Atherosclerosis Society

Related search

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2019English

Controversial Issues of Pathogenesis and Lipid-Lowering Therapy of Atherosclerosis

Clinical pharmacology and therapy
2019English

Three-Year Dynamics and Unsolved Problems of Lipid-Lowering Therapy

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2015English

Functional Evaluation of Lipid-Lowering Therapy by Pravastatin Response

Circulation
Cardiovascular MedicinePhysiologyCardiology
1998English

Circulating PCSK9 Is Lowered Acutely Following Surgery

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2017English

Key Recent Advances in Atherosclerosis Treatment With Modern Lipid-Lowering Drugs: The New Frontier With PCSK9 Inhibitors

European Cardiology Review
Cardiovascular MedicineCardiology
2017English

PCSK9 Inhibitor Improves Cardiac Function and Reduces Infarct Size in Rats With Ischaemia/Reperfusion Injury: Benefits Beyond Lipid‐lowering Effects

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Regression of Atherosclerotic Renal Artery Stenosis With Aggressive Lipid Lowering Therapy

Journal of Human Hypertension
Internal Medicine
2001English

The Role of Aggressive Lipid Lowering Therapy for Coronary Artery Disease

Juntendo Medical Journal
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy